US Patent

US10449159 — Methods and compositions particularly for treatment of attention deficit disorder

Method of Use · Assigned to Purdue Pharma LP · Expires 2035-10-30 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions for treating attention deficit disorder using a coated bead that delays release of a central nervous system stimulant until it reaches the distal intestine.

USPTO Abstract

There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2357 methylphenidate-hydrochloride
U-2357 methylphenidate-hydrochloride
U-2357 methylphenidate-hydrochloride
U-2357 methylphenidate-hydrochloride
U-2357 methylphenidate-hydrochloride
U-2357 methylphenidate-hydrochloride

Patent Metadata

Patent number
US10449159
Jurisdiction
US
Classification
Method of Use
Expires
2035-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Purdue Pharma LP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.